Home/Orlance/Kris Aalto
KA

Kris Aalto

CEO

Orlance

Orlance Pipeline

DrugIndicationPhase
Universal Influenza VaccineInfluenzaPre-IND
Enhanced Seasonal Influenza VaccineInfluenzaResearch
Chronic Hepatitis B VaccineHepatitis BResearch
Neoantigen Cancer Vaccine PlatformOncologyResearch